Cargando…

Understanding the Risks of Immunosuppression Reduction for Active COVID-19 Infection

Detalles Bibliográficos
Autores principales:	Meena, Priti, Crew, R. John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916827/ https://www.ncbi.nlm.nih.gov/pubmed/35309736 http://dx.doi.org/10.1016/j.ekir.2022.03.005

Ejemplares similares

COVID-19 pneumonia, immunosuppression, and cytomegalovirus activation: A perspective
por: Ghosh, K
Publicado: (2021)

Understanding the role of bacterial and fungal infection in COVID-19
por: Rawson, Timothy M., et al.
Publicado: (2021)

Tailoring management and immunosuppression regimen in kidney transplant recipients with COVID-19 infection: lessons from Singapore
por: Chang, Zi Yun, et al.
Publicado: (2021)

The Enigma of Clinical Heterogeneity Among Autosomal Recessive Polycystic Kidney Disease Siblings: PKHD1 Genotype Versus Other Genomic or Environmental Modifier
por: Meena, Priti, et al.
Publicado: (2022)

Infant Circumcision for Sexually Transmitted Infection Risk Reduction Globally
por: Morris, Brian J., et al.
Publicado: (2022)

Imagining a Better Outcome for Chronic Antibody-Mediated Rejection—Will Blocking Interleukin-6 Signaling Help?
por: Muthukumar, Thangamani, et al.
Publicado: (2022)

How Do We Interpret the Presence of Donor-Specific Antibodies When There Is No Rejection?
por: Crew, R. John, et al.
Publicado: (2019)

Understanding vaccine hesitancy in COVID-19
por: Trogen, Brit, et al.
Publicado: (2021)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Immunosuppressive and Proinflammatory Activities of the VacA Toxin of Helicobacter pylori
por: Montecucco, Cesare, et al.
Publicado: (2003)

COVID-19 Infection and Risk for Neuropsychiatric Symptoms
por: Bigos, Kristin L., et al.
Publicado: (2022)

Trend towards reduction in COVID-19 in-hospital mortality
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Understanding the variability of pharmaco‐epidemiological studies assessing the risk of appendicitis with mRNA COVID‐19 vaccines
por: Jambon‐Barbara, Clement, et al.
Publicado: (2022)

Understanding challenges for recovery homes during COVID-19
por: Polcin, Douglas L., et al.
Publicado: (2021)

Commentary: Eye banking, corneal transplantation and the COVID-19 pandemic
por: Karkhur, Samendra, et al.
Publicado: (2023)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

(655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
por: Sauers, E., et al.
Publicado: (2023)

Adherence to Immunosuppression Medications among Heart Transplant Recipients: Challenges, Opportunities, and Potential Role of Digital Approaches in the COVID-19 Era
por: Hussain, Tasmeen, et al.
Publicado: (2021)

BTLA as a biomarker and mediator of sepsis-induced immunosuppression
por: Sherwood, Edward R, et al.
Publicado: (2013)

Understanding Asymptomatic Norovirus Infections
por: Bucardo, Filemón
Publicado: (2018)

COVID-19: Reducing the risk of infection might increase the risk of intimate partner violence
por: van Gelder, N., et al.
Publicado: (2020)

Is it ‘cancer prevention’ or ‘risk reduction’? #Wordsmatter
por: Walker, Desiree A. H., et al.
Publicado: (2021)

Engaging with communities to encourage adoption of a harm reduction approach to COVID-19
por: Hellard, Margaret, et al.
Publicado: (2023)

Understanding and overcoming the immunosuppressive effects of glioma induced immunosuppression
por: Moertel, Christopher, et al.
Publicado: (2013)

Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
por: Sioud, Mouldy
Publicado: (2021)

Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression
por: Swatler, Julian, et al.
Publicado: (2023)

Implications of COVID-19 infections in sickle cell disease
por: John, Nitin Ashok, et al.
Publicado: (2020)

Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19
por: Samet, Jonathan M
Publicado: (2020)

Primaquine plus artemisinin combination therapy for reduction of malaria transmission: promise and risk
por: John, Chandy C.
Publicado: (2016)

On Evidence-Based Practice in Disaster Risk Reduction
por: Alexander, David E.
Publicado: (2021)

Monkeypox stigma and risk communication; Understanding the dilemma
por: Banjar, Weam M., et al.
Publicado: (2023)

Understanding the survivorship burden of long COVID
por: Iqbal, Fahad M., et al.
Publicado: (2021)

Attenuating DNA damage response and immunosuppression radiosensitizes pancreatic cancer
por: Zhang, Yuqing, et al.
Publicado: (2022)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Commentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection
por: Gujral, Jasmine, et al.
Publicado: (2022)

Access to Harm Reduction Treatment Among Formerly Incarcerated Individuals During the COVID-19 Era
por: Rowell-Cunsolo, Tawandra L., et al.
Publicado: (2021)

Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?
por: Malvezzi, Paolo, et al.
Publicado: (2018)

An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia
por: Lee, Jong Hyuk, et al.
Publicado: (2023)

Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions
por: Griffith, Derek M., et al.
Publicado: (2020)

Understanding and Managing Zoonotic Risk in the New Livestock Industries
por: Liverani, Marco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dcl351marj12cieohnmp6gtmbr